All News

RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
SI AS SpA ACR

Spondyloarthritis Innovations

Robert Chao, MD

The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
pso.PsA_.NPF_.jpg

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
PSA2L.jpg

Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments

MedPage Today

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Read Article
Achilles,ankle,heel

GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
Achilles,ankle,heel

ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

Read Article
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
Future treatment for #AxSpA ? Promising data for #Bimekizumab Inhibits IL-17 A and F #RNL2023 https://t.co/H2euMPgIFj
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩ https://t.co/S3NQ4mWgjt
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Eric Dein ericdeinmd ( View Tweet)
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Dr. Rachel Tate uptoTate ( View Tweet)
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review New Drugs in Old Disease? GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb) PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR) @RheumNow https://t.co/cY2HuaI6uM
Eric Dein ericdeinmd ( View Tweet)
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023 https://t.co/d0T2RAssFY
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study https://t.co/S4V3rf4cDc https://t.co/XyZMp1CrsX

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×